NCT01433250 - A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Multiple Sclerosis

Interventions

DRUG

AIN457

(10mg/kg i.v.).

DRUG

AIN457

(10mg/kg i.v.).

Trial Locations (14)

Novartis Investigative Site, Vinnitsya

Novartis Investigative Site, Kharkiv

Novartis Investigative Site, Odesa

Novartis Investigative Site, Moscow

Novartis Investigative Site, Smolensk

Novartis Investigative Site, Kazan'

Novartis Investigative Site, Nizhny Novgorod

Novartis Investigative Site, Hradec Králové

Novartis Investigative Site, Ostrava

Novartis Investigative Site, Ostrava-Moravska Ostrava

Novartis Investigative Site, Kharkiv

Novartis Investigative Site, Kiev

Novartis Investigative Site, Prague

Novartis Investigative Site, Teplice